11/17/2022 8:21:20 AM
PTC Therapeutics : Upstaza Gene Therapy Granted Marketing Authorization For AADC Deficiency By UK's MHRA
7/20/2022 8:08:25 AM
PTC : Upstaza Granted Marketing Authorization By EU As First Disease-Modifying Treatment For AADC Deficiency
6/3/2022 8:05:19 AM
PTC Therapeutics : Preliminary Results Show Promising Clinical Efficacy With Unesbulin In Leiomyosarcoma Study
5/31/2022 1:01:39 AM
PTC Therapeutics : FDA Approves Label Extension For Evrysdi For Infants With Spinal Muscular Atrophy Under 2 Months Old
4/14/2022 8:34:26 AM
PTC Updates On EMA Regulatory Review Timeline For AADC Deficiency Gene Therapy Program; CHMP Opinion Expected May 2022
1/10/2022 7:14:44 AM
PTC Therapeutics Reports $536 Mln 2021 Total Revenue Represents 41% Year-over-year Growth
1/4/2022 8:07:44 AM
Waylivra Gets Innovative Drug Category Pricing To Treat Familial Chylomicronemia Syndrome In Brazil